Phase I study of oral gemcitabine prodrug

Apr 13, 2017 - Keywords: gemcitabine, LY2334737, erlotinib, oral administration ...... disposition of gemcitabine, and oncolytic deoxycytidine analog,...

0 downloads 0 Views 433KB Size

Recommend Documents

indicate this fact. Requests for reprints: Thierry Le Chevalier, Department of Medicine, ..... In most multicenter trials of double chemo- therapy combinations in ...

ANTICANCER RESEARCH 30: 3817-3822 (2010). 3820. Table V. Toxicity. Toxicity. Grade 1 .... C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Postlberger.

Apr 10, 2017 - IgG-negative control signals (assay background) were assigned a value of 1, and ... PCR fragments were then analyzed by Surveyor Nuclease.

comfort and cramping, was the principal dose-limiting tox- icity of S-1 on this .... of 1,000/l associated with fever (38.5°C); (f) omission of. 25% of the planned dose ...

May 18, 1995 - African medicinal plants: 11. Hypoxoside ... Van der Merwe MJ, Jenkins K. Theron E, Van der Wait SJ. ... The quantitative sequestration of rooperol metabolites in ... by the chemical pathology and haematology laboratories at.

Stephen P. Letrent,2 Bharat Damle,2. Arthur P. DeCillis,2 and Eric K. Rowinsky1. 1Institute for ... which fewer than two of the first six new patients experi- enced dose-limiting toxicity. The pharmacokinetic profiles .... a once-daily schedule to im

Mar 15, 2010 - Note: This article is part of a two-part study of PD-0325901. ...... C, Kaplan-Meier analysis of PFS in patients with pERK decrease ≥60% versus .... committee for the NCI; sat on a data safety monitoring committee for Syn- dax.

3 weeks (15 doses/course) followed by 2– 4 weeks of rest. The. DLTs occurring ... patients with RAEB, RAEB in transformation, and CMML (9). ..... Twenty-one febrile episodes ...... Miller, K. B., Kim, K., Morrison, F. S., Winter, J. N., Bennett, J.

9-AC,3 9-nitrocamptothecin, topotecan, irinotecan, karenitecin, and DX-8951f ... of 12 weeks, adequate bone marrow reserve (defined as ab- solute neutrophil ...

tumors. Clin Cancer Res; 1–8. Ó2014 AACR. Introduction. The Hedgehog (Hh) signaling pathway is a key regulator of cell growth, self-renewal, patterning, and differentiation during ... cancer, and soft tissue- or cartilage-derived sarcoma) that wer

the possibility of circadian. FU kinetics contributing to the results. A 28-day schedule ... II studies, although toxicity requiring cessation of drug administration prior ..... have been documented to benefit from fluoropyrimidines, even after faili

them, to break down all of the components of the ECM, includ- ing the basement membrane (1). ... novel synthetic hydroxamic acid derivative (Fig. 1) able to .... (free base). 1913 ..... We wish to thank Drs. T. S. Ganesan and N. Dobbs (Imperial.

Jan 21, 2013 - Chang, Michael Shi, and Andrea Kay are employees of Novartis ...... Grünwald V, Ravaud A, Castellano DE, Lin C, Gschwend JE, et al. A.

Oct 13, 2009 - Experimental Design: Cancer patients (n = 81) received oral doses of lapatinib ranging ... tute, 250 25th Avenue North, Suite 110, Nashville, TN 37203. ..... intestinal obstruction (8%), nausea (6%), vomiting (6%), and dehy-.

Oct 13, 2006 - the adaptation and evaluation of the SFP10–14 ... Twenty-one percent of pupils ... 15–19 years are 16 times more likely to die than those of a ...

Oct 30, 2009 - vincristine and cyclophosphamide (ADOC) reported an overall RR of 92% and .... ctcaev3.pdf (1 May 2009, date last accessed). 13. Kaplan EL ...

Jan 22, 2012 - Clinical Study. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic. Squamous Cell Carcinoma of the Head and ... 2 Division of Hematology/Oncology, St. John Hospital, Wayn

Jan 7, 2015 - polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: ...

... (E) Employment; (H) Honoraria received; (OI) Ownership interests; (IP). Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board. ABSTRACT ... combination regimens (i.e., doxorubicin, ifosfamide, cisplatin, gemcitabine

Keywords: Peripheral T-cell lymphoma, Relapsed, Refractory, Gemcitabine, Romidepsin .... angioimmunoblastic T-cell lymphoma (AITL), and 1 (5 %) patient had ...

Key words: adenocarcinoma, advanced oesophageal cancer, cisplatin, gemcitabine, ... oesophageal cancer, survival is poor after surgery due to local and.

2Hospital General De Occidente, Tucídides 103, Zona Minerva, Guadalajara, Jal. C.P. 44690, Jalisco;. 3Hospital Regional Especialidades, Instituto Mexicano del Seguro Social Monterrey, Nuevo León;. 4Centro Médico del Potosí, Antonio Aguilar # 155

Patients and methods:Patients received ruxolitinib + gemcitabine (regimen A) or ruxolitinib + gemcitabine + .... granulocyte colony-stimulating factor (GCSF) support could ... ing for as long as the regimen was tolerated and the patient.

gemcitabine, a feasibility study of its combination with vinorelbine and prednisolone was planned in relapsed/ refractory HL. This pilot study was conducted to.